Cognition granted FDA nod to study eye disease candidate
hapabapa
- Clinical-stage pharma Cognition Therapeutics (NASDAQ:CGTX) announced Wednesday that the FDA cleared its Investigational New Drug (IND) application for the oral eye disease candidate CT1812.
- The IND was aimed at studying CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD), a form of vision loss commonly found in people over 50.
- The company expects to start its Phase 2 MAGNIFY trial for the candidate this year for dry AMD patients with measurable GA.
- The randomized, placebo-controlled is expected to enroll about 246 people who will be assessed for measures such as GA lesion size and best-corrected visual acuity to see if the treatment can slow vision loss.
- "Expansion of our pipeline programs into GA is an excellent example of how we are leveraging our scientific expertise to tackle some of the most challenging diseases," Chief Executive Lisa Ricciardi noted.
- Cognition (CGTX) which targets its lead candidate CT1812 for early Alzheimer's disease, is a Strong Buy on Wall Street.